AngioDynamics Inc (ANGO) - Total Liabilities
Based on the latest financial reports, AngioDynamics Inc (ANGO) has total liabilities worth $87.32 Million USD as of February 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ANGO net asset momentum to track the company's year-over-year net asset growth rate.
AngioDynamics Inc - Total Liabilities Trend (2002–2025)
This chart illustrates how AngioDynamics Inc's total liabilities have evolved over time, based on quarterly financial data.
AngioDynamics Inc Competitors by Total Liabilities
The table below lists competitors of AngioDynamics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alandsbanken Abp B
HE:ALBBV
|
Finland | €4.84 Billion |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
China | CN¥4.31 Billion |
|
S.C. CHIMCOMPLEX S.A.
RO:CRC
|
Romania | RON990.32 Million |
|
Rieter Holding AG
SW:RIEN
|
Switzerland | CHF734.00 Million |
|
Huchems
KO:069260
|
Korea | ₩259.89 Billion |
|
Deutsche Beteiligungs AG
XETRA:DBAN
|
Germany | €207.06 Million |
|
Hankook Shell Oil
KO:002960
|
Korea | ₩59.90 Billion |
|
Cub Elecparts Inc
TW:2231
|
Taiwan | NT$6.49 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down AngioDynamics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ANGO market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AngioDynamics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AngioDynamics Inc (2002–2025)
The table below shows the annual total liabilities of AngioDynamics Inc from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-05-31 | $97.17 Million | -13.30% |
| 2024-05-31 | $112.08 Million | -27.38% |
| 2023-05-31 | $154.34 Million | +20.33% |
| 2022-05-31 | $128.26 Million | +5.15% |
| 2021-05-31 | $121.98 Million | -12.65% |
| 2020-05-31 | $139.64 Million | -36.99% |
| 2019-05-31 | $221.62 Million | +36.07% |
| 2018-05-31 | $162.88 Million | -14.69% |
| 2017-05-31 | $190.93 Million | -13.62% |
| 2016-05-31 | $221.04 Million | -3.31% |
| 2015-05-31 | $228.60 Million | -12.84% |
| 2014-05-31 | $262.26 Million | -1.05% |
| 2013-05-31 | $265.05 Million | +31.42% |
| 2012-05-31 | $201.69 Million | +534.27% |
| 2011-05-31 | $31.80 Million | -2.39% |
| 2010-05-31 | $32.58 Million | -10.77% |
| 2009-05-31 | $36.51 Million | -31.16% |
| 2008-05-31 | $53.03 Million | +12.07% |
| 2007-05-31 | $47.32 Million | +248.94% |
| 2006-05-31 | $13.56 Million | +28.40% |
| 2005-05-31 | $10.56 Million | -15.46% |
| 2004-05-31 | $12.49 Million | -51.13% |
| 2003-05-31 | $25.57 Million | +22.09% |
| 2002-05-31 | $20.94 Million | -- |
About AngioDynamics Inc
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall … Read more